<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070120</url>
  </required_header>
  <id_info>
    <org_study_id>ICR-CTSU/2013/10041</org_study_id>
    <secondary_id>2013-005095-18</secondary_id>
    <nct_id>NCT02070120</nct_id>
  </id_info>
  <brief_title>Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer</brief_title>
  <acronym>CALIBER</acronym>
  <official_title>CALIBER - A Phase II Randomised Feasibility Study of Chemoresection and Surgical Management in Low Risk Non Muscle Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of&#xD;
      frequent low grade recurrence, which usually necessitates surgical intervention under general&#xD;
      anaesthetic. This multicentre study aims to establish the short term efficacy of&#xD;
      chemoresection using chemotherapy within the bladder for the treatment of NMIBC.&#xD;
&#xD;
      Should the levels of complete response following chemoresection meet predefined criteria, a&#xD;
      larger phase III trial would be developed to assess longer term disease related endpoints,&#xD;
      with the aim of standardising management of recurrent low risk NMIBC and potentially removing&#xD;
      the need for over a thousand patients each year to undergo surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CALIBER is a two stage phase II, multicentre, randomised controlled trial (RCT). A control&#xD;
      group has been included to provide prospective data about surgical management and outcomes&#xD;
      and assess feasibility of recruitment to a randomised study.&#xD;
&#xD;
      Stage 1: 80 patients will be recruited with treatment allocated 2:1 by randomisation between&#xD;
      chemoresection and surgical management.&#xD;
&#xD;
      Stage 2: If the stop/go activity criteria at the end of stage 1 indicate that recruitment&#xD;
      should continue, 9 additional participants will be recruited, all of whom will receive&#xD;
      chemoresection.&#xD;
&#xD;
      Patients assigned to the chemoresection group will receive 4 once weekly intravesical&#xD;
      instillations of 40mg Mitomycin C (MMC) as outpatients. This treatment will be delivered via&#xD;
      catheter under local anaesthetic.&#xD;
&#xD;
      Patients assigned to the surgical management group will receive the standard surgical&#xD;
      management in use at their hospital for treatment of recurrence which may include a single&#xD;
      post-operative installation of 40mg MMC within 24 hours.&#xD;
&#xD;
      All participants will be followed up at 3 weeks from the start of treatment (ie at time of&#xD;
      final MMC instillation for chemoresection group) and each will receive a cystoscopy three&#xD;
      months from the end of treatment to assess response, in accordance with European Association&#xD;
      of Urology (EAU) guidelines.&#xD;
&#xD;
      Subsequent cystoscopic follow up will take place 12 months after treatment if recurrence-free&#xD;
      at 3 months and then annually.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate with chemoresection</measure>
    <time_frame>3 months</time_frame>
    <description>Defined as an absence of any tumour following chemoresection and will be assessed visually at 3 month check cystoscopy by patients' urologists. A biopsy of the tumour bed would take place to confirm visual assessment of complete response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance in chemoresection group</measure>
    <time_frame>Duration of treatment (3 weeks)</time_frame>
    <description>Patients who receive 4 MMC instillations with no more than 14 days between each instillation will be described as fully compliant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salvage surgery rates</measure>
    <time_frame>3 years</time_frame>
    <description>Assessing trans-urethral resection and biopsy rates following initial treatment in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as time from randomisation to the first of muscle invasive bladder recurrence, recurrence in the pelvic nodes, distant metastatic recurrence or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4 and Clavien Dindo grade (in surgical group))</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Measuring side effects of both treatments using clinician reported toxicity scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Superficial Bladder Cancer (BLS24) questionnaire</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Assessing side effects and impact of both treatments on patient reported quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health service utilisation</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Assessed using prospective data collection of health resource usage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free interval</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Time from end of treatment to first relapse, in patients confirmed recurrence free at 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoresection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 once weekly outpatient intravesical instillations 40mg Mitomycin C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical Management</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgical management according to local practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.</description>
    <arm_group_label>Chemoresection</arm_group_label>
    <other_name>MMC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Management</intervention_name>
    <description>Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.</description>
    <arm_group_label>Surgical Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or&#xD;
             Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables&#xD;
&#xD;
          -  Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis&#xD;
&#xD;
          -  Aged 16 or over&#xD;
&#xD;
          -  Satisfactory pre-treatment haematology values and serum creatinine &lt; 1.5 x Upper Limit&#xD;
             of Normal (ULN)&#xD;
&#xD;
          -  Negative pregnancy test for women of child-bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant&#xD;
             carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per&#xD;
             year since initial diagnosis or in the past five years, whichever is shorter&#xD;
&#xD;
          -  Any history of histologically confirmed non-TCC bladder cancer&#xD;
&#xD;
          -  Trial entry recurrence identified within 11.5 months of the date of the original&#xD;
             diagnosis&#xD;
&#xD;
          -  Any prior treatment of the trial entry recurrence (including biopsy)&#xD;
&#xD;
          -  Previous MMC chemotherapy other than a single instillation at diagnostic surgery&#xD;
&#xD;
          -  Known allergy to MMC&#xD;
&#xD;
          -  Carcinoma involving the prostatic urethra or upper urinary tract (participants should&#xD;
             have had imaging of the upper urinary tract within 2 years prior to randomisation)&#xD;
&#xD;
          -  Known or suspected reduced bladder capacity (&lt;100ml)&#xD;
&#xD;
          -  Significant bleeding disorder&#xD;
&#xD;
          -  Female patients who are breast-feeding or are of childbearing potential and unwilling&#xD;
             or unable to use adequate non-hormonal contraception. Male patients should also use&#xD;
             contraception if sexually active.&#xD;
&#xD;
          -  Active or intractable urinary tract infection&#xD;
&#xD;
          -  Urethral stricture or anything impeding the insertion of a catheter&#xD;
&#xD;
          -  Large narrow neck diverticula&#xD;
&#xD;
          -  Significant urinary incontinence&#xD;
&#xD;
          -  Any other conditions that in the Principal Investigator's opinion would contraindicate&#xD;
             protocol treatment&#xD;
&#xD;
          -  Unable or unwilling to comply with study procedures or follow up schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh Mostafid</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Surrey County Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Macclesfield District General Hospital</name>
      <address>
        <city>Macclesfield</city>
        <state>Cheshire</state>
        <zip>SK10 3BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>Cleveland</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Cumberland Hospital</name>
      <address>
        <city>Whitehaven</city>
        <state>Cumbria</state>
        <zip>CA28 8JG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorset County Hospital</name>
      <address>
        <city>Dorchester</city>
        <state>Dorset</state>
        <zip>DT1 2JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Infirmary</name>
      <address>
        <city>Carlisle</city>
        <state>England</state>
        <zip>CA2 7HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broomfield Hospital</name>
      <address>
        <city>Chelmsford</city>
        <state>Essex</state>
        <zip>CM1 5ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Harlow</city>
        <state>Essex</state>
        <zip>CM20 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <state>Gloucestershire</state>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <state>Gloucestershire</state>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Oldham Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>OL1 2JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire Hospital</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hereford County Hospital</name>
      <address>
        <city>Hereford</city>
        <state>Herefordshire</state>
        <zip>HR1 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darent Valley Hospital</name>
      <address>
        <city>Dartford</city>
        <state>Kent</state>
        <zip>DA2 8DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medway Maritime Hospital</name>
      <address>
        <city>Gillingham</city>
        <state>Kent</state>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Headington</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>Suffolk</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Croydon University Hospital</name>
      <address>
        <city>Croydon</city>
        <state>Surrey</state>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <state>West Midlands</state>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Richard's Hospital</name>
      <address>
        <city>Chichester</city>
        <state>West Sussex</state>
        <zip>PO19 6SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Worthing</city>
        <state>West Sussex</state>
        <zip>BN11 2DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinderfields General Hospital</name>
      <address>
        <city>Wakefield</city>
        <state>West Yorkshire</state>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidderminster Hospital</name>
      <address>
        <city>Kidderminster</city>
        <state>Worcestershire</state>
        <zip>DY11 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra Hospital</name>
      <address>
        <city>Redditch</city>
        <state>Worcestershire</state>
        <zip>B98 7UB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worcester Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Worcestershire</state>
        <zip>WR5 1DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Withington Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 2LR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Mostafid AH, Porta N, Cresswell J, Griffiths TRL, Kelly JD, Penegar SR, Davenport K, McGrath JS, Campain N, Cooke P, Masood S, Knowles MA, Feber A, Knight A, Catto JWF, Lewis R, Hall E. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. BJU Int. 2020 Jun;125(6):817-826. doi: 10.1111/bju.15038. Epub 2020 Apr 3.</citation>
    <PMID>32124514</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonmuscle invasive bladder cancer (NMIBC)</keyword>
  <keyword>Mitomycin C</keyword>
  <keyword>Chemoresection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

